Axsome Executive's $3.6M Stock Sales Signal Potential Strategy Shift
Rhea-AI Filing Summary
Form 144 Notice Filing for Axsome Therapeutics (NASDAQ: AXSM) details proposed sale of securities by insider Hunter R. Murdock. The filing indicates a planned sale of 6,014 shares of common stock with an aggregate market value of $602,101, to be executed through Charles Schwab & Co.
The shares were acquired through an Employee Stock Option Exercise on June 23, 2025, with payment made via a cashless exercise through broker. The filing reveals significant recent insider trading activity by the same individual over the past three months:
- June 20, 2025: 7,500 shares sold for $768,503
- June 18, 2025: 7,500 shares sold for $756,729
- June 17, 2025: 7,500 shares sold for $751,975
- June 16, 2025: 7,500 shares sold for $768,154
Total outstanding shares reported: 49,236,365. The proposed sale represents a continuation of systematic insider selling pattern, with approximately 30,000 shares sold in the preceding month.
Positive
- None.
Negative
- Insider Hunter R. Murdock executed multiple significant sales totaling 30,000 shares worth approximately $3 million over a 5-day period in June 2025, indicating substantial selling pressure from management
- The insider is planning an additional sale of 6,014 shares worth approximately $602,101, continuing the selling pattern
FAQ
How many AXSM shares were sold by Hunter R. Murdock in June 2025?
What is the proposed sale amount in AXSM's latest Form 144 filing?
How did the AXSM insider acquire the shares being sold?
What was AXSM's total shares outstanding according to the June 2025 Form 144?
What was the average price per share of AXSM insider sales in June 2025?